PTGXHIGH SIGNALFINANCIAL10-K

PTGX experienced a dramatic financial reversal, swinging from $275.2M net income to a $130.1M loss, representing a $405M negative shift in profitability.

This represents a fundamental change in the company's financial trajectory, with operating income declining by 162.5% from positive $252.8M to negative $158.1M. The magnitude of this swing suggests either the end of a major one-time revenue event or significant operational deterioration that investors need to understand immediately.

Comparing 2026-02-25 vs 2025-02-21View on EDGAR →
FINANCIAL ANALYSIS

PTGX's financials show a stark reversal from profitability to significant losses, with net income swinging from positive $275.2M to negative $130.1M and operating cash flow declining 68.7% to $57.7M. While R&D expenses increased a manageable 15.3% and the company improved its cash position by 32% to $128.4M with reduced liabilities, the core profitability collapse of over $400M suggests either the end of major milestone payments or partnership revenues. The improved balance sheet metrics provide some cushion, but the operational performance deterioration represents a fundamental shift that requires immediate investor attention.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+253.8%
$169K→$598K

Interest expense surged 253.8% — significant debt increase or rising rates materially impacting earnings.

Operating Income
P&L
-162.5%
$252.8M→-$158.1M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Net Income
P&L
-147.3%
$275.2M→-$130.1M

Net income declined 147.3% — review whether driven by operations, interest costs, or non-recurring items.

Operating Cash Flow
Cash Flow
-68.7%
$184.2M→$57.7M

Operating cash flow fell 68.7% — earnings quality concerns; investigate working capital changes and non-cash items.

Cash & Equivalents
Balance Sheet
+32%
$97.2M→$128.4M

Cash position surged 32% — strong cash generation or capital raise providing significant financial cushion.

Total Liabilities
Balance Sheet
-23%
$69.4M→$53.5M

Liabilities reduced 23% — deleveraging improves balance sheet strength and financial flexibility.

R&D Expense
P&L
+15.3%
$138.1M→$159.3M

R&D investment increased 15.3% — signals commitment to future product development, though near-term margin impact.

Total Assets
Balance Sheet
-10.3%
$744.7M→$668.2M

Total assets contracted 10.3% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2026-02-25
PRIOR — 2025-02-21
ADDED
There were 63,808,716 shares of registrant s Common Stock, par value $0.00001 per share, outstanding as of February 18, 2026.
If we are unable to discover and develop new product candidates, our business would be adversely affected.
Our product candidates may cause undesirable side effects or have other properties adversely impacting safety that delay or prevent their regulatory approval, restrict their approved labeling, or otherwise limit their commercial opportunity.
Unstable market and macroeconomic conditions, including tariffs or trade policy, may have serious adverse consequences on our business, financial condition and stock price.
If we require additional capital, there may be dilution to our existing stockholders.
+7 more — sign up free →
REMOVED
There were 61,384,289 shares of registrant s Common Stock, par value $0.00001 per share, outstanding as of February 19, 2025.
Our product candidates may cause undesirable side effects or have other properties adversely impacting safety that delay or prevent their regulatory approval, restrict their approved labeling, or otherwise limit their commercial opportunity, including being required by an independent data monitoring committee or regulatory authorities to delay or halt or clinical trials, or if such side effects or adverse events are sufficiently severe or prevalent, to suspend or cease altogether further development of our product candidates.
We have never generated any revenue from product sales and may never be profitable.
Unstable market and macroeconomic conditions including elevated and sustained inflation and changes in trade policies, including tariffs or other trade restrictions or the threat of such actions, may have serious adverse consequences on our business, financial condition and stock price.
Raising additional capital may cause dilution to our existing stockholders.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →